| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/CBT.2.5.440 |
| P8608 | Fatcat ID | release_gyvbv4ymgzadlbt2gc2o4jcegy |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.4161/cbt.2.5.440 |
| https://www.tandfonline.com/doi/pdf/10.4161/cbt.2.5.440?needAccess=true | ||
| P698 | PubMed publication ID | 14614316 |
| P5875 | ResearchGate publication ID | 9012388 |
| P50 | author | David T. Curiel | Q64384545 |
| Anna Kanerva | Q64398934 | ||
| P2093 | author name string | Igor Dmitriev | |
| Gerd Bauerschmitz | |||
| Angel A. Rivera | |||
| Dirk M. Nettelbeck | |||
| Andrea L. Volk | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| oncology | Q162555 | ||
| Adenoviridae | Q193447 | ||
| genetic vector | Q427389 | ||
| gene delivery | Q2790163 | ||
| molecular medicine | Q3523816 | ||
| P304 | page(s) | 511-515 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism | |
| Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism | |||
| P478 | volume | 2 |
| Q35874291 | A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents |
| Q36468656 | Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism |
| Q97589304 | CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression |
| Q47560447 | Cancer Terminator Viruses (CTV): A Better Solution for Viral-Based Therapy of Cancer. |
| Q35142325 | Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes |
| Q26995655 | Circumventing antivector immunity: potential use of nonhuman adenoviral vectors |
| Q40088612 | Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells |
| Q45117334 | Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells |
| Q40459504 | Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. |
| Q39812421 | Defining the role of CD46, CD80 and CD86 in mediating adenovirus type 3 fiber interactions with host cells. |
| Q39864968 | E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies |
| Q40514543 | Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways |
| Q90698268 | Engineering protein nanocages as carriers for biomedical applications |
| Q39740442 | Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells |
| Q35587169 | Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells |
| Q35186312 | Gene Therapies for Cancer: Strategies, Challenges and Successes |
| Q39948164 | Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells |
| Q35695549 | Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop |
| Q40350503 | Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells |
| Q45856180 | Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses |
| Q34667746 | Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism |
| Q39067827 | Novel oncolytic viral therapies in patients with thoracic malignancies |
| Q33273469 | Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression |
| Q34426949 | Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma |
| Q39616158 | Oncolytic adenovirus based on serotype 3. |
| Q39410097 | Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. |
| Q64245487 | Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses |
| Q40264235 | Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. |
| Q37109089 | Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas |
| Q35779378 | Tissue-specific promoters for cancer gene therapy |
| Q34183436 | Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. |
| Q59354245 | Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX |
| Q40189728 | Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q33425253 | Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses |
| Q91768182 | Unravelling Receptor and RGD Motif Dependence of Retargeted Adenoviral Vectors using Advanced Tumor Model Systems |
| Q35609031 | mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine |
Search more.